Evidence map›Paper›PMID 41131532›Full record

ReviewInfectious agents and cancer2025

COVID-19 infection and cancer regression: a review of current evidence, potential mechanisms, and clinical perspectives on a Paradoxical phenomenon.

Ikponmwosa Jude Ogieuhi, Victor Oluwatomiwa Ajekiigbe, Chinonyelum Emmanuel Agbo, Chidera Stanley Anthony, Adegbesan Abiodun Christopher, Jennifer Chinaecherem Onyehalu, Mercy Chisom Agu, Sylvia Mmesomachi Mbaji, Adewunmi Akingbola, Bisharat Ahmed and 2 more

Abstract readReview
In one paragraph

Review in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ikponmwosa Jude OgieuhiSiberian State Medical University, Tomsk, Russia. jude.ogieuhi@gmail.com.
Victor Oluwatomiwa AjekiigbeLadoke Akintola University of Technology, Ogbomosho, Nigeria.
Chinonyelum Emmanuel AgboUniversity of Nigeria, Nsukka, Nigeria.
Chidera Stanley AnthonyUniversity of Calabar, Calabar, Nigeria.
Adegbesan Abiodun ChristopherDepartment of Global Health, Stellenbosch University, Cape Town, South Africa.
Jennifer Chinaecherem OnyehaluUniversity of Nigeria, Nsukka, Nigeria.
Mercy Chisom AguUniversity of Nigeria, Nsukka, Nigeria.
Sylvia Mmesomachi MbajiUniversity of Nigeria, Nsukka, Nigeria.
Adewunmi AkingbolaUniversity of Cambridge Cambridgeshire Old Trinity Schools, Cambridge, England, CB2 1TN, UK.
Bisharat AhmedAllama Iqbal Medical College, Lahore, Pakistan.
Owa OgieuhiFederal Neuro-Psychiatric Hospital, Benin City, Nigeria.
Olufemi AkinmejiOlabisi Onabanjo University, Sagamu, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since its emergence, the coronavirus (SARS-CoV-2) outbreak has been a pandemic responsible for about 7 million deaths worldwide. Numerous studies have been conducted to determine the virus's multiorgan system involvement, particularly its relation to cancer biology. Spontaneous regression of cancer has been observed in some patients with the coronavirus, which may be attributed to the virus's ability to trigger specific immune responses that can be oncolytic and help reduce and eliminate oncogenic cells. This study aims to explore the paradoxical effects of COVID-19 in inducing cancer regression. The paradoxical effect of SARS-CoV-2 infection has been attributed to the possibility of a heightened immune activation possibly triggered by the virus, and some of these include increased levels of cytokines such as interferon and tumor necrosis factor-alpha (TNF-α), as well as the activation of T cells and natural killer (NK) cells. COVID-19-induced cancer regression presents new perspectives on the relationship between viral infections and the immune system's antitumor capabilities. This would help foster future research investigating specific immune pathways activated during SARS-CoV-2 and discover how these can be therapeutically harnessed to aid cancer regression.

Indexed as

CancerCOVID-19Immune systemNoveltySARSSpontaneous regression

Identifiers

PMID41131532
PMCPMC12548167

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.